Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Goserelin
Drug ID BADD_D01038
Description Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Indications and Usage Used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.
Marketing Status Prescription
ATC Code L02AE03
DrugBank ID DB00014
KEGG ID D04405
MeSH ID D017273
PubChem ID 5311128
TTD Drug ID D00BCG
NDC Product Code 70720-951; 55463-0005; 70720-950
Synonyms Goserelin | ICI-118630 | ICI 118630 | ICI118630 | Zoladex | Goserelin Acetate | Acetate, Goserelin
Chemical Information
Molecular Formula C59H84N18O14
CAS Registry Number 65807-02-5
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C( CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C 6CCC(=O)N6
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metastases to liver16.22.02.001; 09.04.02.0040.000384%Not Available
Metastases to lung22.08.01.005; 16.22.02.0020.000384%Not Available
Metastases to spine16.22.02.007; 15.09.03.0070.001471%Not Available
Metrorrhagia21.01.01.0060.001471%Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood altered19.04.02.0070.001471%Not Available
Mood swings19.04.03.0010.002206%Not Available
Multiple fractures15.08.02.005; 12.04.02.009--Not Available
Muscle spasms15.05.03.0040.002942%
Muscular weakness15.05.06.001; 17.05.03.0050.005884%
Myalgia15.05.02.0010.003677%
Myelodysplastic syndrome16.01.04.001; 01.10.04.0010.000384%
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Neoplasm malignant16.16.01.0010.000384%Not Available
Nephrolithiasis20.04.01.0020.001471%
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Night sweats08.01.03.031; 23.02.03.0060.001471%Not Available
Nocturia20.02.03.001--Not Available
Oedema14.05.06.010; 08.01.07.0060.001471%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.002206%
Oestradiol increased13.10.05.0140.001471%Not Available
Ophthalmoplegia17.17.02.005; 06.05.02.003--Not Available
Osteoarthritis15.01.04.001--Not Available
Osteomyelitis15.02.05.001; 11.01.01.0010.001471%
Osteoporosis15.02.03.002; 14.04.04.0020.001471%
Ovarian cyst21.11.01.002; 16.04.03.001--Not Available
Ovarian hyperstimulation syndrome21.11.02.007; 05.05.01.013--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages